Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Bayer Pharma Aktiengesellschaft has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are distributed among 5 distinct examiners and 5 distinct art units. GEMBEH, SHIRLEY V is the busiest examiner with 1 busiest examiner pending action. The portfolio is perfectly distributed across 5 distinct examiners and 5 distinct art units.
Because each of the 5 pending office actions is in a different art unit and with a different examiner, there is no administrative overlap in the current portfolio. This structure means that the outcome of one action is unlikely to be influenced by the same examiner handling another. GEMBEH, SHIRLEY V, as the busiest examiner with 1 pending action, represents the same workload as every other official in this set. Practitioners must manage 5 separate relationships across 5 different organizational groups at the office. The 5 distinct art units involved show that the 5 pending office actions cover several different sub-specialties within the biotechnology field.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
| GEMBEH, SHIRLEY V | 1 | 63.2% | +34.0% |
| LOCKARD, JON MCCLELLAND | 1 | 74.6% | +27.2% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| SAMALA, JAGADISHWAR RAO | 1 | 68.0% | +55.6% |
| MCMILLIAN, KARA RENITA | 1 | 30.7% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | MCMILLIAN, KARA RENITA | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336769 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | LOCKARD, JON MCCLELLAND | 42d overdue |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | SAMALA, JAGADISHWAR RAO | 31d overdue |
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | MCMILLIAN, KARA RENITA | 34d |
| 18964918 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | MCKOY, QUINCY ANDRE | — |
| 18725470 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | GEMBEH, SHIRLEY V | — |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | PUTTLITZ, KARL J | — |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1647 | 1 |
| 1646 | 1 |
| 1621 | 1 |
| 1618 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18964918 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | MCKOY, QUINCY ANDRE | — | DP | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18725470 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | GEMBEH, SHIRLEY V | 1615 | Other | Final Rejection | — | Pending | Jun 28, 2024 |
| 18336769 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | LOCKARD, JON MCCLELLAND | 1647 | §112Other | Final Rejection | 42d overdue | Pending | Jun 16, 2023 |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | PUTTLITZ, KARL J | 1646 | DP | Non-Final OA | — | Pending | Feb 27, 2023 |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | O DELL, DAVID K | 1621 | §103 | Final Rejection | — | Pending | Nov 17, 2022 |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | SAMALA, JAGADISHWAR RAO | 1618 | §112DP | Final Rejection | 31d overdue | Pending | Nov 02, 2022 |
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | MCMILLIAN, KARA RENITA | 1623 | §101Other | Final Rejection | 34d | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial